MEP20408A - Pharmaceutical dronedarone composition for parenteral administration - Google Patents

Pharmaceutical dronedarone composition for parenteral administration

Info

Publication number
MEP20408A
MEP20408A MEP-204/08A MEP20408A MEP20408A ME P20408 A MEP20408 A ME P20408A ME P20408 A MEP20408 A ME P20408A ME P20408 A MEP20408 A ME P20408A
Authority
ME
Montenegro
Prior art keywords
pharmaceutical
parenteral administration
dronedarone
composition
dronedarone composition
Prior art date
Application number
MEP-204/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Sanofi-Synthelabo
Frederique Bourriague-Seve
Thierry Breul
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of MEP20408A publication Critical patent/MEP20408A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
MEP-204/08A 2000-12-11 2001-12-10 Pharmaceutical dronedarone composition for parenteral administration MEP20408A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0016071A FR2817750B1 (fr) 2000-12-11 2000-12-11 Composition pharmaceutique de dronedarone pour administration parenterale
PCT/FR2001/003903 WO2002047660A1 (fr) 2000-12-11 2001-12-10 Composition pharmaceutique de dronedarone pour administration parenterale

Publications (1)

Publication Number Publication Date
MEP20408A true MEP20408A (en) 2010-06-10

Family

ID=8857483

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2008-204A ME00083B (me) 2000-12-11 2001-12-10 Farmaceutski oblik dronedarona za parenteralnu upotrebu
MEP-204/08A MEP20408A (en) 2000-12-11 2001-12-10 Pharmaceutical dronedarone composition for parenteral administration

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MEP-2008-204A ME00083B (me) 2000-12-11 2001-12-10 Farmaceutski oblik dronedarona za parenteralnu upotrebu

Country Status (31)

Country Link
US (1) US6939865B2 (xx)
EP (1) EP1343473B1 (xx)
JP (1) JP4399161B2 (xx)
KR (1) KR100849758B1 (xx)
CN (1) CN1235566C (xx)
AR (1) AR031649A1 (xx)
AT (1) ATE348599T1 (xx)
AU (2) AU1722902A (xx)
BG (1) BG66187B1 (xx)
BR (1) BR0116060B1 (xx)
CA (1) CA2427375C (xx)
CZ (1) CZ297788B6 (xx)
DE (1) DE60125411T2 (xx)
EA (1) EA005314B1 (xx)
FR (1) FR2817750B1 (xx)
HK (1) HK1055906A1 (xx)
HU (1) HU229372B1 (xx)
IL (2) IL155428A0 (xx)
IS (1) IS2349B (xx)
MA (1) MA26969A1 (xx)
ME (2) ME00083B (xx)
MX (1) MXPA03005221A (xx)
NO (1) NO332294B1 (xx)
NZ (1) NZ525661A (xx)
OA (1) OA12416A (xx)
PL (1) PL199846B1 (xx)
RS (1) RS50348B (xx)
SK (1) SK287115B6 (xx)
TW (1) TWI246926B (xx)
WO (1) WO2002047660A1 (xx)
ZA (1) ZA200303406B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200800177A (en) * 2006-02-14 2008-01-01 Wyeth Corp Aqueous pharmaceutical formulations of ERβ selective ligands
GB0719180D0 (en) * 2007-10-02 2007-11-14 Cambrex Karlskoga Ab New process
FR2930149B1 (fr) * 2008-04-17 2011-02-18 Sanofi Aventis Association de dronedarone avec au moins un diuretique, son application en therapeutique
AR072950A1 (es) 2008-04-17 2010-10-06 Sanofi Aventis Uso de dronedarona para la preparacion de un medicamento para uso en la prevencion de la hospitalizacion cardiovascular o de la mortalidad, composicion farmaceutica, articulo de fabricacion y envase
EP2116239A1 (en) * 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
FR2959132A1 (fr) * 2010-04-22 2011-10-28 Sanofi Aventis Procedes pour l'evaluation et la reduction des risques
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
US20120005128A1 (en) * 2010-06-29 2012-01-05 Sanofi Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
CN102342907A (zh) 2010-07-30 2012-02-08 江苏恒瑞医药股份有限公司 决奈达隆固体分散体及其制备方法
KR20120094557A (ko) * 2011-02-01 2012-08-27 동아제약주식회사 피에이치 비의존적 용출양상을 갖는 부정맥치료제 제제
CN102908307A (zh) * 2011-08-03 2013-02-06 天津市嵩锐医药科技有限公司 供注射用盐酸决奈达隆药物组合物及其制备方法
MA37753B1 (fr) * 2012-07-12 2019-04-30 Sanofi Sa Composition antitumorale comprenant le composé 1-(6-{[6-(4-fluorophényl)[1,2,4]triazolo[4,3-b] pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-yléthyl)urée
CN114377148B (zh) * 2020-10-20 2023-09-29 上海博志研新药物研究有限公司 盐酸决奈达隆药物组合物、其制备方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
FR2746013B1 (fr) * 1996-03-18 1998-05-29 Sanofi Sa Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus
JP2004327321A (ja) * 2003-04-25 2004-11-18 Jst Mfg Co Ltd コネクタ

Also Published As

Publication number Publication date
BG66187B1 (bg) 2011-12-30
BR0116060A (pt) 2004-03-02
CN1235566C (zh) 2006-01-11
EP1343473B1 (fr) 2006-12-20
RS50348B (sr) 2009-11-10
CZ297788B6 (cs) 2007-03-28
MA26969A1 (fr) 2004-12-20
NZ525661A (en) 2004-11-26
EP1343473A1 (fr) 2003-09-17
KR100849758B1 (ko) 2008-07-31
EA005314B1 (ru) 2004-12-30
EA200300406A1 (ru) 2003-10-30
IL155428A0 (en) 2003-11-23
CA2427375A1 (fr) 2002-06-20
DE60125411T2 (de) 2007-10-11
KR20030060985A (ko) 2003-07-16
SK7262003A3 (en) 2004-02-03
NO20031958L (no) 2003-06-11
AU1722902A (en) 2002-06-24
SK287115B6 (sk) 2009-12-07
PL362788A1 (en) 2004-11-02
AU2002217229B2 (en) 2006-05-18
CN1479610A (zh) 2004-03-03
WO2002047660A1 (fr) 2002-06-20
US20040044070A1 (en) 2004-03-04
CA2427375C (fr) 2011-02-01
IS6801A (is) 2003-04-30
PL199846B1 (pl) 2008-11-28
NO332294B1 (no) 2012-08-20
US6939865B2 (en) 2005-09-06
DE60125411D1 (de) 2007-02-01
BR0116060B1 (pt) 2013-12-31
JP2004528277A (ja) 2004-09-16
HUP0500842A2 (hu) 2005-12-28
OA12416A (fr) 2006-04-18
HK1055906A1 (en) 2004-01-30
YU46503A (sh) 2006-08-17
FR2817750B1 (fr) 2003-02-21
AR031649A1 (es) 2003-09-24
ZA200303406B (en) 2004-05-03
ATE348599T1 (de) 2007-01-15
IS2349B (is) 2008-04-15
TWI246926B (en) 2006-01-11
HU229372B1 (en) 2013-11-28
FR2817750A1 (fr) 2002-06-14
CZ20031612A3 (cs) 2003-09-17
MXPA03005221A (es) 2004-03-26
IL155428A (en) 2007-10-31
BG107748A (bg) 2004-03-31
ME00083B (me) 2010-10-10
NO20031958D0 (no) 2003-04-29
JP4399161B2 (ja) 2010-01-13

Similar Documents

Publication Publication Date Title
MEP20408A (en) Pharmaceutical dronedarone composition for parenteral administration
HRP20020880B1 (en) New pharmaceutical composition
MEP33708A (en) Pharmaceutical compositions comprising a hmg coa reductase inhibitor
EE05081B1 (et) Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, 3-aminoasetidiini derivaadid ja nende valmistamise meetodid
NO20025621D0 (no) Farmasöytisk sammensetning med vedvarende frigjöring for parenteral administrasjon av hydrofile forbindelser
HUP0302086A2 (hu) Késleltetett hatású orális gyógyászati készítmény és eljárás az előállítására
RS51746B (sr) Atorvastatin kalcijum u farmaceutskom obliku, njegovoj smeši i farmaceutskoj formulaciji, koja sadrži atorvastatin kalcijum
MEP39108A (en) Pharmaceutical composition
DK1766003T3 (da) Thrombinpræparater
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
ME00180B (me) Kiseli preparati insulina sa poboljšanom stabilnošću
HRP20010243B1 (en) Compositions containing diphosphonic acids
CY1112139T1 (el) Μια φαρμακευτικη συνθεση περιλαμβανουσα κρυσταλλικη ριτοναβιρη μορφη ιι και ενα παρασκευασμα εξ αυτης
MY122124A (en) Solid pharmaceutical composition containing benzofurane derivatives
ES2174083T3 (es) Composicion farmaceutica de amiodarona para administracion parenteral.
ATE198834T1 (de) Konjugate bestehend aus polysaccharid und protein
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
DK1104289T3 (da) Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
DE69921486D1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
FR2793685B1 (fr) Compositions pharmaceutiques, destinees a l'administration par voie orale de phloroglucinol et leur preparation
SE0001916D0 (sv) Novel formulation
HRP20010764B1 (en) Prucalopride oral solution
MXPA03004111A (es) Composiciones de n-(1 -metiletilaminocarbonil)-4 -(3-metilfenilamino) -3-piridil-sulfonamida y oligosacaridos ciclicos con una mayor liberacion.
MEP18508A (en) Pharmaceutical composition and preparation thereof
FR2789078B3 (fr) Derives d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant